<?xml version='1.0' encoding='utf-8'?>
<document id="18448569"><sentence text="Effects of ketoconazole and quinidine on pharmacokinetics of pactimibe and its plasma metabolite, R-125528, in humans."><entity charOffset="11-23" id="DDI-PubMed.18448569.s1.e0" text="ketoconazole" /><entity charOffset="28-37" id="DDI-PubMed.18448569.s1.e1" text="quinidine" /><pair ddi="false" e1="DDI-PubMed.18448569.s1.e0" e2="DDI-PubMed.18448569.s1.e0" /><pair ddi="false" e1="DDI-PubMed.18448569.s1.e0" e2="DDI-PubMed.18448569.s1.e1" /></sentence><sentence text="Pactimibe sulfate is a novel acyl coenzyme A:cholesterol acyltransferase inhibitor developed for the treatment of hypercholesterolemia and atherosclerotic diseases"><entity charOffset="0-17" id="DDI-PubMed.18448569.s2.e0" text="Pactimibe sulfate" /><entity charOffset="29-33" id="DDI-PubMed.18448569.s2.e1" text="acyl" /><entity charOffset="45-56" id="DDI-PubMed.18448569.s2.e2" text="cholesterol" /><entity charOffset="57-67" id="DDI-PubMed.18448569.s2.e3" text="acyl" /><pair ddi="false" e1="DDI-PubMed.18448569.s2.e0" e2="DDI-PubMed.18448569.s2.e0" /><pair ddi="false" e1="DDI-PubMed.18448569.s2.e0" e2="DDI-PubMed.18448569.s2.e1" /><pair ddi="false" e1="DDI-PubMed.18448569.s2.e0" e2="DDI-PubMed.18448569.s2.e2" /><pair ddi="false" e1="DDI-PubMed.18448569.s2.e0" e2="DDI-PubMed.18448569.s2.e3" /><pair ddi="false" e1="DDI-PubMed.18448569.s2.e1" e2="DDI-PubMed.18448569.s2.e1" /><pair ddi="false" e1="DDI-PubMed.18448569.s2.e1" e2="DDI-PubMed.18448569.s2.e2" /><pair ddi="false" e1="DDI-PubMed.18448569.s2.e1" e2="DDI-PubMed.18448569.s2.e3" /><pair ddi="false" e1="DDI-PubMed.18448569.s2.e2" e2="DDI-PubMed.18448569.s2.e2" /><pair ddi="false" e1="DDI-PubMed.18448569.s2.e2" e2="DDI-PubMed.18448569.s2.e3" /></sentence><sentence text=" Pactimibe has two equally dominant clearance pathways forming R-125528 by CYP3A4 and M-1 by CYP2D6 in vitro"><entity charOffset="1-10" id="DDI-PubMed.18448569.s3.e0" text="Pactimibe" /></sentence><sentence text=" R-125528 is a plasma metabolite and is cleared solely by CYP2D6 despite its acidity" /><sentence text=" To evaluate contributions of the cytochrome P450 enzymes on the pharmacokinetics of pactimibe and R-125528 in humans, drug-drug interaction studies using ketoconazole and quinidine were conducted"><entity charOffset="155-167" id="DDI-PubMed.18448569.s5.e0" text="ketoconazole" /><entity charOffset="172-181" id="DDI-PubMed.18448569.s5.e1" text="quinidine" /><pair ddi="false" e1="DDI-PubMed.18448569.s5.e0" e2="DDI-PubMed.18448569.s5.e0" /><pair ddi="false" e1="DDI-PubMed.18448569.s5.e0" e2="DDI-PubMed.18448569.s5.e1" /></sentence><sentence text=" Eighteen healthy male subjects were given a single dose of pactimibe sulfate without and with 400 mg of ketoconazole (q"><entity charOffset="60-77" id="DDI-PubMed.18448569.s6.e0" text="pactimibe sulfate" /><entity charOffset="105-117" id="DDI-PubMed.18448569.s6.e1" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.18448569.s6.e0" e2="DDI-PubMed.18448569.s6.e0" /><pair ddi="false" e1="DDI-PubMed.18448569.s6.e0" e2="DDI-PubMed.18448569.s6.e1" /></sentence><sentence text="d" /><sentence text=")" /><sentence text=" With the concomitant treatment, the area under the plasma concentration-time curve (AUC(0-inf)) of pactimibe modestly increased 1" /><sentence text="7-fold and AUC(0-tz) of R-125528 decreased by 55%" /><sentence text=" In addition, 17 healthy male subjects were given a single dose of pactimibe sulfate without and with 600 mg of quinidine (b"><entity charOffset="67-84" id="DDI-PubMed.18448569.s11.e0" text="pactimibe sulfate" /><entity charOffset="112-121" id="DDI-PubMed.18448569.s11.e1" text="quinidine" /><pair ddi="false" e1="DDI-PubMed.18448569.s11.e0" e2="DDI-PubMed.18448569.s11.e0" /><pair ddi="false" e1="DDI-PubMed.18448569.s11.e0" e2="DDI-PubMed.18448569.s11.e1" /></sentence><sentence text="i" /><sentence text="d" /><sentence text=")" /><sentence text=" With the concomitant treatment, the AUC(0-inf) for pactimibe modestly increased 1" /><sentence text="7-fold" /><sentence text=" On the other hand, the AUC(0-tz) of R-125528 was markedly elevated 5" /><sentence text="0-fold, although the AUC(0-inf) could not be adequately defined because the terminal elimination phase of R-125528 was not obtained in the study period up to 72 h" /><sentence text=" As the f(m CYP3A4) and f(m CYP2D6) values of pactimibe estimated from in vitro studies were 0" /><sentence text="40 and 0" /><sentence text="33, respectively, AUC increase ratios of pactimibe were estimated to be 1" /><sentence text="7 with ketoconazole and 1"><entity charOffset="7-19" id="DDI-PubMed.18448569.s22.e0" text="ketoconazole" /></sentence><sentence text="5 with quinidine"><entity charOffset="7-16" id="DDI-PubMed.18448569.s23.e0" text="quinidine" /></sentence><sentence text=" These values were well in accordance with the values observed in this study" /><sentence text=" Moreover, the f(m CYP2D6) of R-125528 estimated to be almost 1 would well explain the accumulation of R-125528 observed with the quinidine treatment"><entity charOffset="130-139" id="DDI-PubMed.18448569.s25.e0" text="quinidine" /></sentence><sentence text="" /></document>